A simple and sensitive LC-MS/MS method for determination and quantification of potential genotoxic impurities in the ceritinib active pharmaceutical ingredient

被引:9
作者
Antolcic, Mia [1 ]
Runje, Mislav [1 ]
Galic, Nives [2 ]
机构
[1] Pliva Croatia, TAPI R&D, Prilaz Baruna Filipovica 25, Zagreb 10000, Croatia
[2] Univ Zagreb, Fac Sci, Dept Chem, Harvatavac 102a, Zagreb 10000, Croatia
关键词
ANAPLASTIC LYMPHOMA KINASE; CLINICOPATHOLOGICAL FEATURES;
D O I
10.1039/d0ay00511h
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used for quantification of four potential genotoxic impurities (PGIs) in the ceritinib active pharmaceutical ingredient. Chromatographic separation was achieved using a YMC-Triart C18 column, with 0.1% formic acid in water as mobile phase A and acetonitrile as mobile phase B in gradient elution mode at a 0.5 mL min(-1)flow rate. Quantification of impurities was carried out using triple quadrupole mass detection with electrospray ionization in multiple reaction monitoring mode. The method was fully validated with good linearity over the concentration range of 0.5-5.0 ppm of the ceritinib test concentration for all four PGIs. The correlation coefficient obtained in each case was >0.998. The recoveries were found satisfactory over the range between 83.7 and 107.3% for all selected impurities. The developed method was able to quantitate all four PGIs at a concentration level of 1 ng mL(-1)(0.5 ppm with respect to 2 mg mL(-1)ceritinib).
引用
收藏
页码:3290 / 3295
页数:6
相关论文
共 18 条
  • [1] Adhao VS, 2017, INDONES J PHARM, V28, P241, DOI 10.14499/indonesianjpharm28iss4pp241
  • [2] [Anonymous], 2008, GEN CARC IMP DRUG SU
  • [3] [Anonymous], 2005, INT C HARM VAL AN PR, VQ2
  • [4] [Anonymous], EMEACHMP1670682004
  • [5] [Anonymous], 2011, INT C HARM TECHN REQ
  • [6] Babu G. S., 2017, J SYNTHETIC NATURAL, V2, P7
  • [7] A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor
    Bao, Xun
    Wu, Jianmei
    Sanai, Nader
    Li, Jing
    [J]. JOURNAL OF PHARMACEUTICAL ANALYSIS, 2018, 8 (01) : 20 - 26
  • [8] The anaplastic lymphoma kinase in the pathogenesis of cancer
    Chiarle, Roberto
    Voena, Claudia
    Ambrogio, Chiara
    Piva, Roberto
    Inghirami, Giorgio
    [J]. NATURE REVIEWS CANCER, 2008, 8 (01) : 11 - 23
  • [9] Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
    Iwama, Eiji
    Okamoto, Isamu
    Harada, Taishi
    Takayama, Koichi
    Nakanishi, Yoichi
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 375 - 385
  • [10] Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 203 - 214